CYRX Cryoport, Inc.
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-con…
Industry Peers
Integrated Freight & Logistics| Headline | Source | Time |
|---|---|---|
Older | ||
 Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions The latest analyst work on Cryoport points to a higher blended fair value estimate, with price targets moving from US$17.06 to US$19.33, about a 13% uplift in the modeled target level. That shift lines up with more constructive Street commentary, as several bullish analysts highlight Cryoport’s Cell and Gene Therapy logistics and bioservices as key supports for the higher target range. As you read on, you will see how to track these shifting assumptions and what they might mean for your own... | ||
 Cryoport (CYRX) Q2 2026 Earnings Call Transcript CGT services revenue surged 15% as clinical trial support expanded to 779 trials globally. | ||
 CryoPort (CYRX) Upgraded to Buy: Here's Why CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | ||
 Investor Confidence in CryoPort (CYRX) Strengthened Backed by Pipeline Expansion Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […] | ||
 Cryoport, Inc. Q2 2026 Earnings Call Summary Moby summary of Cryoport, Inc.'s Q2 2026 earnings call | ||
CryoPort Inc (CYRX) (Q2 2026) Earnings Call Highlights: Positive EBITDA Milestone and 15% ... CryoPort Inc (CYRX) achieves positive adjusted EBITDA and reaffirms full-year guidance amid strong biostorage growth and expanding commercial therapy support. | ||
 CryoPort Q2 Earnings Call Highlights CryoPort (NASDAQ:CYRX) reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million. Chief Executive Officer Jerrell Shelton said revenue momentum continue | ||
 CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates CryoPort (CYRX) delivered earnings and revenue surprises of 0.00% and +1.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2 Caris Life Sciences,?Inc. (CAI) delivered earnings and revenue surprises of +100.00% and +14.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Targets On Growth Trends Cryoport is back in focus after the modeled fair value in one framework moved from US$15.61 to US$17.06, signaling a higher price target being used in recent analysis. That shift lines up with Street research that has taken a more constructive tone on the stock, with higher targets in the mid to high teens and above US$20 tied to what analysts view as healthier trends across MVE, BioLogistics, and BioStorage. Read on to see how these updated targets fit into the evolving Cryoport narrative... | ||